Neste episódio, vamos analisar os dados do estudo REDEFINE 1 que avaliou o uso da Cagrilintida + Semaglutida (CagriSema) nos pacientes com obesidade, sem diabetes.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
